These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18948412)

  • 21. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids.
    Meibohm B; Derendorf H; Möllmann H; Fröhlich P; Tromm A; Wagner M; Homrighausen S; Krieg M; Hochhaus G
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):367-76. PubMed ID: 10475139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.
    Sharma A; Davis CB; Tobia LA; Kwok DC; Tucci MG; Gore ER; Herzyk DJ; Hart TK
    J Pharmacol Exp Ther; 2000 Apr; 293(1):33-41. PubMed ID: 10734150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
    Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
    Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
    Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finding a way out: lymphocyte egress from lymphoid organs.
    Schwab SR; Cyster JG
    Nat Immunol; 2007 Dec; 8(12):1295-301. PubMed ID: 18026082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists.
    Evindar G; Bernier SG; Doyle E; Kavarana MJ; Satz AL; Lorusso J; Blanchette HS; Saha AK; Hannig G; Morgan BA; Westlin WF
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2520-4. PubMed ID: 20304639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor.
    Walzer T; Chiossone L; Chaix J; Calver A; Carozzo C; Garrigue-Antar L; Jacques Y; Baratin M; Tomasello E; Vivier E
    Nat Immunol; 2007 Dec; 8(12):1337-44. PubMed ID: 17965716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
    Brossard P; Derendorf H; Xu J; Maatouk H; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2013 Dec; 76(6):888-96. PubMed ID: 23594176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice.
    Morohoshi K; Osone M; Yoshida K; Nakagawa Y; Hoshikawa S; Ozaki H; Takahashi Y; Ito S; Mori K
    Autoimmunity; 2011 Sep; 44(6):490-5. PubMed ID: 21457062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary and vascular pharmacology of sphingosine 1-phosphate.
    Brinkmann V; Baumruker T
    Curr Opin Pharmacol; 2006 Jun; 6(3):244-50. PubMed ID: 16563863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral pharmacokinetic and pharmacodynamic effects of FTY720 in cats.
    Downes S; Chen YJ; Kyles A; Gregory C
    J Vet Pharmacol Ther; 2007 Feb; 30(1):55-61. PubMed ID: 17217402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells.
    Damirin A; Tomura H; Komachi M; Tobo M; Sato K; Mogi C; Nochi H; Tamoto K; Okajima F
    Mol Pharmacol; 2005 Apr; 67(4):1177-85. PubMed ID: 15625281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter by Xia regarding article, "High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor".
    Xia P
    Circulation; 2007 Apr; 115(14):e393; author reply e394. PubMed ID: 17420358
    [No Abstract]   [Full Text] [Related]  

  • 37. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
    Deguchi Y; Andoh A; Yagi Y; Bamba S; Inatomi O; Tsujikawa T; Fujiyama Y
    Oncol Rep; 2006 Oct; 16(4):699-703. PubMed ID: 16969482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of sphingosine 1-phosphate modulation on immune outcomes.
    Pinschewer DD; Brinkmann V; Merkler D
    Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
    Angst D; Janser P; Quancard J; Buehlmayer P; Berst F; Oberer L; Beerli C; Streiff M; Pally C; Hersperger R; Bruns C; Bassilana F; Bollbuck B
    J Med Chem; 2012 Nov; 55(22):9722-34. PubMed ID: 23067318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.